The original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding a milder infection.
COVID-19 vaccine makers have been updating their shots to better match omicron in case global health authorities decide the change is needed.
“We recognize the need to be prepared in the event this protection wanes over time and to potentially help address omicron and new variants in the future,” Kathrin Jansen, Pfizer’s vaccine research chief, said in a statement. In one study group, about 600 volunteers who received two doses of the current Pfizer vaccine three to six months ago will receive either one or two omicron-based shots as boosters. Another 600 who’ve already gotten three regular doses of the Pfizer vaccine will be given a fourth dose of either the regular vaccine or the omicron-matched version.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer opens study of COVID shots updated to match omicronPfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious omicron variant. Pfizer...
Baca lebih lajut »
Pfizer opens study of COVID shots updated to match omicronPfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.
Baca lebih lajut »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Baca lebih lajut »
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine studyCOVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
Baca lebih lajut »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Baca lebih lajut »
Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Baca lebih lajut »